



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2559958 C 2013/04/16

(11)(21) **2 559 958**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2005/03/07
(87) Date publication PCT/PCT Publication Date: 2005/09/15
(45) Date de délivrance/Issue Date: 2013/04/16
(85) Entrée phase nationale/National Entry: 2006/08/29
(86) N° demande PCT/PCT Application No.: JP 2005/004384
(87) N° publication PCT/PCT Publication No.: 2005/084698
(30) Priorité/Priority: 2004/03/09 (JP2004-066410)

(51) Cl.Int./Int.Cl. *A61K 38/17* (2006.01),
A61K 38/20 (2006.01)
(72) Inventeurs/Inventors:
KUBO, HIROSHI, JP;
ISHIZAWA, KOTA, JP;
SASAKI, HIDETADA, JP;
NAKAMURA, TOSHIKAZU, JP
(73) Propriétaire/Owner:
KRINGLE PHARMA INC., JP
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : AGENT D'INDUCTION DE DIFFERENCIATION OU DE REGENERATION POUR DES ALVEOLES
(54) Title: A DIFFERENTIATION- OR REGENERATION-INDUCING AGENT FOR ALVEOLI

(57) **Abrégé/Abstract:**

The present invention provides an agent comprising HGF for inducing differentiation of bone marrow cells into alveolar cells. The present invention also provides an HGF-containing agent for alveolar formation in pulmonary emphysema and the like in which alveoli are destroyed.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/084698 A1

(51) International Patent Classification⁷: **A61K 38/17,**
38/20

(74) Agent: IWATANI, Ryo; ORIX Dojima Bldg. 3F, 1-31,
Dojima 2-chome, Kita-ku, Osaka-shi, Osaka 530-0003
(JP).

(21) International Application Number:
PCT/JP2005/004384

(22) International Filing Date: 7 March 2005 (07.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2004-066410 9 March 2004 (09.03.2004) JP

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **TO-HOKU TECHNOARCH CO., LTD.** [JP/JP]; Office of Research Promotion and Intellectual Property, 1-1, Katahira 2-chome, Aoba-ku, Sendai-shi, Miyagi 980-8577 (JP). **KRINGLE PHARMA INC.** [JP/JP]; 8F Senri Asahi Hankyu Bldg., 5-3, Shinsenrihigashimachi 1-chome, Toyonaka-shi, Osaka 560-0082 (JP).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KUBO, Hiroshi** [JP/JP]; 17-3, Kunimigaoka 1-chome, Aoba-ku, Sendai-shi, Miyagi 989-3201 (JP). **ISHIZAWA, Kota** [JP/JP]; 11-15-102, Tsunogoro 2-chome, Aoba-ku, Sendai-shi, Miyagi 980-0874 (JP). **SASAKI, Hidetada** [JP/JP]; 9-2, Mukaiyama 1-chome, Taihaku-ku, Sendai-shi, Miyagi 982-0841 (JP). **NAKAMURA, Toshikazu** [JP/JP]; 1-4, Hoshojicho, Okazaki, Sakyo-ku, Kyoto-shi, Kyoto 606-8333 (JP).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A DIFFERENTIATION- OR REGENERATION-INDUCING AGENT FOR ALVEOLI

(57) Abstract: The present invention provides an agent comprising HGF for inducing differentiation of bone marrow cells into alveolar cells. The present invention also provides an HGF-containing agent for alveolar formation in pulmonary emphysema and the like in which alveoli are destroyed.

WO 2005/084698 A1

DESCRIPTION

A differentiation- or regeneration-inducing agent for alveoli

5 Technical Field

The present invention relates to an agent comprising
hepatocyte growth factor as an active ingredient for inducing
differentiation of bone marrow cells into alveolar cells, and
also relates to an agent for forming alveoli by such
10 differentiation induction.

Background Art

Hepatocyte growth factor (hereinafter referred to as HGF)
was originally identified as a growth factor for mature
15 hepatocytes, and its gene (cDNA) was cloned in 1989 (see
non-patent literatures 1 and 2).

It has been revealed so far that HGF exerts various
biological activities such as cell proliferation, promotion of
cell migration, morphogenesis induction, cell death inhibition
20 and the like on various cells as well as hepatocytes (see
non-patent literatures 3 to 6).

The biological activities of HGF are expressed via its
receptor, i.e. c-Met tyrosine kinase. HGF has various
biological activities and has functions of repairing and
25 protecting various tissues from various injuries.

Angiogenesis promoting activity is one of HGF functions
of regeneration or protection of tissues. HGF not only promotes
proliferation and migration of vascular endothelial cells, but
also shows in vivo potent angiogenesis-inducing activity (see

non-patent literatures 7 to 10).

Further, HGF has an activity of inhibiting cell death of vascular endothelial cells (see non-patent literatures 11 to 13).

5 Lung is an organ composed of a large number of alveoli. The air taken into the body by respiration is passed through trachea and then enters into bronchi. Bronchi are further branched, and one bronchiole is connected to one alveolus. Human alveolus is a small sac of about 0.2 mm diameter, and is
10 surrounded by capillaries. Gas exchange takes place in the alveoli, i.e., oxygen is taken from the inspired gas entered through the bronchi into the alveoli, and carbon dioxide in the blood is exhausted into the alveoli as expired gas. Pulmonary emphysema is physiologically a progressive destruction of the
15 alveoli, and the surface area of alveoli available for gas exchange is reduced as disease progresses. Inadequate gas exchange in the alveoli causes a shortage of oxygen in the blood. With the progress of the disease, lung elasticity is lowered, resulting in respiratory difficulty. In addition, since adult
20 lung is an organ which cannot spontaneously grow or regenerate itself, pulmonary emphysema is considered to be a progressive and irreversible disease. Massaro et. al reported that treatment with all-trans-retinoic acid (ATRA) anatomically and physiologically regenerated lung in an animal model of
25 pulmonary emphysema (see non-patent literature 14). Further, ATRA is known to activate genes involved in lung development and to promote alveolar septation and growth of lung. However, clinical trials using ATRA failed to show significant improvement in lung structure or lung function in pulmonary

emphysema patients (see non-patent literature 15).

It has been reported that HGF promotes the growth of alveolar epithelial type II cells or bronchial epithelial cells, and that HGF is involved in the repair of alveolar epithelial
5 cells (see non-patent literatures 16-19). Also, a study on the effect of HGF on acute lung injury revealed that HGF is newly produced in the lung after injury, and that when HGF is administered to animals with an injured lung, cell proliferation in the lung tissue is stimulated and repair of
10 the injured lung is promoted (see patent literature 2).

However, any of the above-mentioned literatures does not describe that HGF induces differentiation of bone marrow cells into alveolar cells and that regeneration or formation of alveoli is promoted by such differentiation induction.

15 [Patent literature 1] JP-A-89869/1996

[Patent literature 2] JP-A-172207/1994

[Non-patent literature 1] Biochemical and Biophysical Research Communications, 1984, vol. 122, p. 1450-1459

20 [Non-patent literature 2] Nature, 1989, vol. 342, p.440-443

[Non-patent literature 3] The Journal of Cell Biology, 1985, vol. 129, p.1177-1185

[Non-patent literature 4] The Journal of Biochemistry, 1986, vol. 119, p.591-600

25 [Non-patent literature 5] International Review of Cytology), 1999, vol.186, p.225-260

[Non-patent literature 6] Kidney International, 2001, vol. 59, p.2023-2038

[Non-patent literature 7] The Journal of Cell Biology,

1992, vol.119, p.629-641

[Non-patent literature 8] Proceedings of the National Academy of Sciences of the United States of America, 1993, vol. 90, p.1937-1941

5 [Non-patent literature 9] Circulation, 1998, vol. 97, p.381-390

[Non-patent literature 10] Hypertension, 1999, vol. 33, p.1379-1384

10 [Non-patent literature 11] Journal of Hypertension, 2000, vol.18, p.1411-1420

[Non-patent literature 12] Hypertension, 2001, vol. 37, p.581-586

[Non-patent literature 13] Diabetes, 2002, vol. 51, p.2604-2611

15 [Non-patent literature 14] Massaro,G.D., et. al, Nature Medicine, 1997, vol. 3, p.675-677

[Non-patent literature 15] Mao,J.T., et. al, American Journal of Respiratory & Critical Care Medicine, 2002, vol. 165, p.718-723

20 [Non-patent literature 16] Mason RJ, et. al, American Journal of Respiratory Cell and Molecular Biology, 1994, vol. 11, p.561-567

[Non-patent literature 17] Shiratori M, et. al, American Journal of Respiratory Cell and Molecular Biology, 1995, vol. 12, p.171-180

[Non-patent literature 18] Ohmichi H, et. al, The American Journal of Physiology, 1996, vol. 270, p.L1031-L1039

[Non-patent literature 19] Sakamaki,Y, et. al, American Journal of Respiratory Cell and Molecular Biology, 2002, vol.

30079-67

5

26, p. 525-533.

Disclosure of Invention

An object of the present invention is to provide an agent for inducing differentiation of bone marrow cells into alveolar cells. Another object of the present invention is to utilize the above differentiation-inducing agent as an agent for promoting regeneration of damaged alveoli or alveolar formation.

The present inventors have newly found that damaged alveoli observed in, for example, pulmonary emphysema are regenerable, the regenerated alveoli are differentiated from bone marrow cells, and HGF induces such differentiation. As a result of extensive studies based on these findings, the present inventors have completed the present invention.

Namely, the present invention relates to:

(1) An agent for inducing differentiation of bone marrow cells into alveolar cells comprising hepatocyte growth factor,

(2) The differentiation-inducing agent according to the above (1), wherein the alveolar cells are alveolar epithelial cells, and

(3) The differentiation-inducing agent according to the above (1) or (2), which is an agent for promoting alveolar regeneration or formation.

Specific aspects of the invention include:

- a composition for inducing differentiation of bone marrow cells into alveolar cells, comprising hepatocyte growth factor and a pharmaceutically acceptable additive, the hepatocyte growth factor being (a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or (b) hepatocyte growth factor comprising an amino acid sequence of 90% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence

30079-67

5a

of SEQ ID NO: 1 and having an activity to induce differentiation of bone marrow cells into alveolar cells;

- a composition for inducing differentiation of bone marrow cells into alveolar cells, comprising hepatocyte growth factor and a pharmaceutically acceptable additive, the hepatocyte growth factor being (a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or (b) hepatocyte growth factor comprising an amino acid sequence of 95% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1 and having an activity to induce differentiation of bone marrow cells into alveolar cells;

- a hepatocyte growth factor for use in inducing differentiation of bone marrow cells into alveolar cells, which is (a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or (b) hepatocyte growth factor comprising an amino acid sequence of 90% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1 and having an activity to induce differentiation of bone marrow cells into alveolar cells; and

- a hepatocyte growth factor for use in inducing differentiation of bone marrow cells into alveolar cells, which is (a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or (b) hepatocyte growth factor comprising an amino acid sequence of 95% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1 and having an activity to induce differentiation of bone marrow cells into alveolar cells.

Also, the present invention relates to a method for inducing differentiation of bone marrow cells into alveolar cells by administration of HGF to mammals, and further relates to the use of HGF to produce medicines for inducing differentiation of bone marrow cells into alveolar cells.

Further, the present invention relates to a method for culturing bone marrow cells together with a differentiation-inducing agent containing HGF, and transplanting the alveolar cells differentiated from the bone marrow cells to mammals, or a
5 method for culturing bone marrow cells, transplanting the proliferated bone marrow cells to mammals, administering simultaneously a differentiation-inducing agent containing HGF, and inducing differentiation of the transplanted bone marrow cells into alveolar cells. Furthermore, the present
10 invention includes a gene therapy for regeneration of damaged alveoli or new alveolar formation comprising introduction of HGF gene as well as administration of HGF.

Since the differentiation-inducing agent of the present invention induces differentiation of bone marrow cells into
15 alveolar cells, new alveoli can be formed in a disease in which alveoli are destroyed such as pulmonary emphysema, pulmonary fibrosis with honey-comb lung, pulmonary lymphangiomyomatosis (LAM), destroyed lung after pulmonary resection and the like
Further, when bone marrow cells are cultured in the presence
20 of a differentiation-inducing agent of the present invention, alveolar cells differentiated from the bone marrow cells can be prepared.

Furthermore, the alveolar cells differentiated from bone marrow cells obtained by culturing bone marrow cells together
25 with a differentiation-inducing agent of the present invention can be utilized as cells for transplantation in the field of regenerative medicine.

Brief Explanation of the Drawing

30079-67

7

Fig. 1 shows histological findings in the lung of pulmonary emphysema-induced recipient mice.

Fig. 2 shows a mean linear intercept of alveoli in pulmonary emphysema-induced recipient mice.

5 Fig. 3 shows a rate of GFP positive cells relative to alveolar cells in the lung of pulmonary emphysema-induced recipient mice.

Best Mode for Carrying Out the Invention

10 HGF used in the present invention is a known substance. HGF prepared by various processes can be used in the present invention as long as it is purified enough to be used as a medical agent. Regarding production processes of HGF, for example, HGF can be obtained by cultivating primary culture cells or cells
15 of an established cell line which produce HGF, isolating HGF from culture supernatant or the like and purifying the isolated HGF. Alternatively, recombinant HGF can also be obtained according to a genetic engineering technique by integrating a gene encoding HGF into an appropriate vector, inserting the
20 vector into proper host cells for transformation thereof and collecting the target recombinant HGF from the culture supernatant of the transformed cells (see, for example, JP-A-111383/1993; Biochem. Biophys. Res. Commun., 1989, vol. 163, p.967).

25 The above-mentioned host cells are not particularly limited, and various kinds of host cells conventionally used in the genetic engineering techniques, such as Escherichia coli, yeast, animal cells or the like may be used. The obtained HGF, so long as it has substantially the same action as natural HGF,

may include substitution, deletion, addition and/or insertion of one or more (e.g., several) of amino acids in the amino acid sequence thereof. Similarly, HGF may include substitution, deletion and/or addition of sugar chain(s). Here "the deletion, substitution, addition or insertion of one or more of amino acids" in the amino acid sequence means that the amino acids in a number that can naturally occur (one to several amino acids) may be deleted, substituted, added and/or inserted into the amino acid sequence by known technical methods such as genetic engineering techniques, site-specific mutation induction and the like.

Also, "HGF including substitution, deletion and/or addition of sugar chain(s)" means, for example, (1) glycosylation-deficient HGF which is obtained by treating a natural glycosylated HGF with an enzyme to remove sugar chain(s), (2) HGF of which amino acid sequence is mutated at a glycosylation site to inhibit glycosylation, or (3) HGF of which amino acid sequence is mutated in such a manner that glycosylation occurs at a site different from the natural glycosylation site.

Further, HGF also includes a protein having at least 60 % or more homology, preferably 80 % or more homology, more preferably 90 % or more homology, still more preferably 95 % or more homology to the amino acid sequence of HGF and also having an activity to induce differentiation of bone marrow cells into alveolar cells. The above-mentioned "homology" between amino acid sequences generally means the level of homology between the amino acid residues constituting the amino acid sequences when the primary structures of the proteins are compared.

HGF used in the present invention may have a carboxylate (-COO⁻), amide (-CONH₂) or ester (-COOR) as well as a carboxyl group (-COOH) at its C terminal so long as it has substantially the same actions as natural HGF. Here, as R in the ester, 5 optionally substituted lower alkyl groups (e.g., methyl, ethyl, propyl, cyclopentyl, benzyl, phenethyl, etc.), aryl groups (e.g., phenyl, α -naphthyl, etc.), pivaloyloxymethyl groups which are generally used as an ester for oral administration and the like may be mentioned. In addition, HGF usable in the 10 present invention may include HGF in which an amino group of a methionine residue at the N-terminal is protected by a protective group (e.g., an acyl group such as formyl, acetyl, etc.), HGF in which a glutamyl group produced by cutting an N-terminal side in vivo has changed to a pyroglutamic acid and 15 the like.

In the present invention, regeneration or formation of alveoli means new alveolar formation or regeneration of damaged alveoli. Alveoli are a gas exchange organ composed of alveolar epithelial cells, capillaries comprising pulmonary capillary 20 endothelial cells, etc. and connective tissues. Further, the alveoli of the present invention include branched bronchi parts connected to the alveoli.

The differentiation-inducing agent of the present invention can be applied for the purpose of regeneration or 25 formation of alveoli in diseases where alveoli are destroyed, such as pulmonary emphysema, pulmonary fibrosis with honey-comb lung, pulmonary lymphangiomyomatosis (LAM), destroyed lung after pulmonary resection and the like in mammals (e.g. cow, horse, pig, sheep, dog, cat) including human.

The differentiation-inducing agent of the present invention may take various dosage forms such as liquid preparations, solid preparations, capsules and the like, however, it is generally formulated with HGF alone or with a combination of HGF and a conventional carrier into injections, inhalations, suppositories or orally administrable preparations. The above-mentioned injections may be aqueous injections or oily injections.

In the case of aqueous injections, they can be prepared in such a manner that HGF is dissolved in, for example, a solution prepared by appropriately adding a pharmaceutically acceptable carrier such as isotonic agents (e.g. sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, glucose, propylene glycol, etc.), buffers (e.g. phosphoric acid buffer, acetic acid buffer, boric acid buffer, carbonic acid buffer, citric acid buffer, Tris-buffer, glutamic acid buffer, ϵ -aminocarproic acid buffer, etc.), preservatives (e.g. methyl p-oxybenzoate, ethyl p-oxybenzoate, propyl p-oxybenzoate, butyl p-oxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid, borax, etc.), thickeners (e.g. hydroxyethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, polyethylene glycol, etc.), stabilizers (e.g. sodium hydrogensulfite, sodium thiosulfate, sodium edetate, sodium citrate, ascorbic acid, dibutyl hydroxy toluene, etc.), pH control agents (e.g. hydrochloric acid, sodium hydroxide, phosphoric acid, acetic acid, etc.) and the like to an aqueous solvent (e.g. injectable water, purified water, etc.), and then the solution is filtered through a filter, etc., sterilized and

filled in a sterile container according to a known method. Further, appropriate solubilizers such as alcohols (e.g. ethanol, etc.), polyalcohol (e.g. propylene glycol, polyethylene glycol, etc.) or non-ionic surfactants (e.g. polysorbate 80, polyoxyethylene hydrogenated castor oil 50, etc.) may be used.

In the case of oily preparations, sesame oil, soy bean oil and the like are used as an oily solvent, and benzyl benzoate, benzyl alcohol and the like may be used as a solubilizer. The obtained injectable solution is usually filled in an ampoule or a vial. The HGF content in the injection preparation is usually adjusted to about 0.0002 to 0.2 w/v %, preferably about 0.001 to 0.1 w/v %. It is preferable that liquid preparations such as injections are preserved after removing water by freeze-preservation or freeze-drying. The freeze-dried preparation is redissolved in injectable distilled water before use.

In the case of orally administrable preparations, the dosage forms include, for example, tablets, granules, fine granules, powders, capsules, liquids, emulsions, suspensions, syrups and the like. These preparations may be prepared by the conventional method. In the case of granules or tablets, they can be produced by using pharmaceutically acceptable additives such as excipients (e.g. lactose, white sugar, glucose, starch, crystalline cellulose, etc.), lubricants (e.g. magnesium stearate, talc, stearic acid, calcium stearate, etc.), disintegrators (e.g. starch, carmellose sodium, calcium carbonate, etc.), binders (e.g. starch paste, hydroxypropyl cellulose solution, carmellose solution, gum arabic solution,

gelatin solution, sodium alginate solution, etc.), and the like. Also, granules or tablets may be coated with an appropriate coating agent (e.g. gelatin, white sugar, gum arabic, carnauba wax, etc.), enteric coating agents (e.g. cellulose acetate phthalate, methacrylic acid copolymer, hydroxypropyl cellulose phthalate, carboxymethylethyl cellulose, etc.), and the like.

In the case of capsules, known excipients such as magnesium stearate, calcium stearate, talc and light anhydrous silicic acid for enhancing flowability and lubricability; crystalline cellulose or lactose for increasing flowability under pressure; and the above-mentioned disintegrators may be appropriately selected. HGF is homogeneously blended or granulated with the above-mentioned excipient, or the granules may be coated with a suitable coating agent and then filled in a capsule, or the granules may be encapsulated with a capsule base (e.g. gelatin) having increased plasticity which is endowed with addition of glycerin, sorbitol, etc. If required, coloring agents or preservatives (e.g. sulfur dioxide, methyl p-oxybenzoate, ethyl p-oxybenzoate, propyl p-oxybenzoate, butyl p-oxybenzoate, etc.) may be added to the capsule preparation. The capsule preparation may take a form of enteric coated capsule, gastric acid-resistant capsule, release-controlled capsule or the like in addition to conventional capsule preparations.

In the case of enteric coated capsule preparations, HGF coated with an enteric coating agent or HGF to which the above-mentioned suitable excipients are added is filled in a conventional capsule. Alternatively, HGF alone or HGF to which

the above-mentioned suitable excipients are added may be encapsulated in an enteric coated capsule or in a capsule formed from a base material comprising an enteric polymer.

In the case of syrups, stabilizers (e.g. sodium edetate, etc.), suspending agents (e.g. gum arabic, carmellose, etc.), corrigents (e.g. simple syrup, glucose, etc.), perfumes, and the like can be appropriately selected and used.

Further, suppositories can be prepared by the conventional formulation method using a conventional suppository base (e.g. cacao butter, lauric oil, glycerogelatin, macrogol, Witepsol, etc.) and the like.

Furthermore, inhalation preparations may be produced by the conventional formulation method. In the formulation of inhalations, any additives may be used so long as they are commonly utilized for inhalation preparations. For example, in addition to propellants, the above-mentioned excipients, binders, lubricants, preservatives, stabilizers, isotonic agents, pH control agents and corrigents (e.g. citric acid, menthol, ammonium glycyrrhizate, glycine, perfume, etc.) are used. As the propellants, liquefied gas propellants, compressed gas and the like are used. The liquefied gas propellants include, for example, fluorinated hydrocarbons such as alternative chlorofluorocarbons (e.g. HCFC-22, HCFC-123, HCFC-134a, HCFC-142, etc.), liquefied petroleum ether, dimethyl ether, and the like. The compressed gas includes, for example, soluble gas (e.g. carbon dioxide gas, nitrous oxide gas, etc.) and inert gas (e.g. nitrogen gas, etc.).

Moreover, HGF used in the present invention together with

a biodegradable polymer may be formulated into a delayed release preparation. In the delayed release preparations of HGF, such effects as maintenance of blood level, reduction of administration frequency, alleviation of adverse effects, etc. may be expected. Such delayed release preparations can be prepared, for example, according to the conventional method as described in Drug Delivery System, chapter 3, 1986 (published by CMC, Japan). The biodegradable polymer used in the present invention may be appropriately selected from known biodegradable polymers, and include, for example, polysaccharides (e.g. starch, dextran, chitosan, etc.), proteins (e.g. collagen, gelatin, etc.), polyamino acids (e.g. polyglutamic acid, polylysine, polyleucine, polyalanine, polymethionine, etc.), polyesters (e.g. polylactic acid, polyglycolic acid, lactic acid/glycolic acid polymer or copolymer, polycaprolactone, poly- β -hydroxybutyric acid, polymalic acid, poly-acid anhydride, fumaric acid-polyethylene glycol-vinylpyrrolidone copolymer, etc.), poly(ortho esters), polyalkyl-cyanoacrylic acids (e.g. polymethyl- α -cyanoacrylic acid, etc.), polycarbonates (e.g. polyethylene carbonate, polypropylene carbonate, etc.), among which polyesters are preferable, and polylactic acid, lactic acid/glycolic acid polymers or copolymers are more preferable. When a polylactic acid/glycolic acid polymer or copolymer is used, its component ratio (mol %) of lactic acid/glycolic acid is about 100/0 to 50/50 in case of the delayed release time of two weeks to three months, preferably two weeks to one month, though such ratio depends on the delayed release time. The average molecular weight of such polylactic acid/glycolic acid

polymer or copolymer is generally 5,000 to 20,000. The polylactic acid/glycolic acid homopolymer or copolymer can be prepared according to the known method, for example, the method as described in JP-A-28521/1986. Although there is no
5 limitation with respect to mixing ratio of HGF with biodegradable polymer, HGF is used generally in an amount about 0.01 w/w % to 30 w/w % relative to the biodegradable polymer.

HGF content in the above-mentioned preparations may be appropriately adjusted depending on dosage form, indications,
10 degree of diseases, age, etc.

The differentiation-inducing agent of the present invention may appropriately contain other pharmaceutical active ingredients, so long as they are not contrary to the purpose of the present invention. Examples of such active
15 ingredients include, for example, anti-cholinergic agents (e.g. ipratropium bromide, flutropium bromide, oxitropium bromide, tiotropium bromide, etc.), inhalation β_2 stimulants (e.g. fenoterol, salbutamol, formoterol, salmeterol, etc.), inhalation steroids (e.g. beclomethasone, fluticasone, budesonide, etc.), antiasthmatics (e.g. theophylline,
20 procaterol, ketotifen, azelastine, etc.), antiallergics (e.g. ketotifen, terfenadine, azelastine, epinastine, etc.), antiinflammatory agents (e.g. diclofenac sodium, ibuprofen, indomethacin, etc.), antibiotics (e.g. cefmenoxime, cefdinir, ofloxacin, tosfloxacin, norfloxacin, etc.), antimycotics (e.g.
25 fluconazole, itraconazole, etc.) and the like. Also, a preparation containing those pharmaceutical active ingredients may be used in combination with a preparation of the present invention. There is no limitation on those

pharmaceutical active ingredients so long as the purposes of the present invention can be attained, and it is possible to use such active ingredients appropriately in a suitable mixing ratio or a combination ratio.

5 The differentiation-inducing agent of the present invention may be administered via a suitable administration route depending on their dosage form. For example, injections may be administered via intravenous, intraarterial, subcutaneous or intramuscular route and the like. The
10 injection dose is usually 0.001 mg to 1000 mg on the basis of HGF, preferably 0.01 mg to 100 mg, which is appropriately administered once a day or several times a day in a divided manner, although it may be appropriately adjusted depending on the condition, age, body weight of patients, etc.

15 The differentiation-inducing agent of the present invention can be used to induce the differentiation of bone marrow cells into alveolar cells. As the bone marrow cells, any bone marrow cells of mammals including human beings can be used, while it is preferable to use floating bone marrow cells.
20 For example, human bone marrow cells are harvested by the known method, suspended in a cell culture liquid, seeded in a plastic petri dish, and cultured to collect only floating cells therefrom. Subsequently, the floating bone marrow cells are cultured together with a differentiation-inducing agent of the
25 present invention. As the cell culture liquid, a conventional culture liquid such as DMEM, MEM, RPMI1640, IMDM, etc., can be used. Although additives which are commonly used in cell culture, such as fetal bovine serum, may be added to the above-mentioned cell culture liquid, it is preferable to use

a serum-free cell culture liquid in view of transplantation immunology. HGF concentration in the differentiation-inducing agent is about 1 ng/mL to about 100 ng/mL. Culture conditions are those employed in the usual cell culture, for example, at about $35^{\circ}\text{C} \pm 2^{\circ}\text{C}$ in the presence of 5 % carbon dioxide and the like. The bone marrow cells cultured as such are cultured for one to five weeks, resulting in differentiation into alveolar cells. The differentiation-induced alveolar cells derived from the bone marrow cells obtained as above are available as a cell for organ transplantation. To be more specific, by intravenously injecting alveolar cells differentiated and proliferated from bone marrow cells of a pulmonary emphysema patient to the patient, the transplantation into the lung can be achieved. According to this procedure, it is possible to obtain a large amount of alveolar cells needed for transplantation in pulmonary emphysema patients, from the bone marrow cells of the patients themselves.

Further, there may be another embodiment which comprises culturing bone marrow cells, utilizing the resultant proliferated non-differentiated bone marrow cells as a cell for transplantation, and administering a differentiation-inducing agent of the present invention to a recipient. According to the present invention, differentiation induction from the transplanted bone marrow cells to alveolar cells occurs effectively in the body, because a small amount of bone marrow cells harvested from a patient with pulmonary emphysema are cultured and proliferated, and a large amount of the resultant bone marrow cells are returned to the patient at the same time when a differentiation-inducing agent of the present invention

30079-67

18

is administered.

With respect to bone marrow cells to be used in the above-mentioned adoptive transfer, they are preferably those collected from the same individual to be transplanted, in view of transplantation immunology.

5 In recent years, gene therapies using HGF gene have been reported (see Circulation, 1997, vol. 96, No. 3459; Nature Medicine, 1999, vol. 5, p. 226-230; Circulation, 1999, vol. 100, No. 1672; Gene Therapy, 2000, vol. 7, p. 417-427), and such gene therapies have been technologically established. The present invention includes a gene therapy agent comprising introduction of HGF gene for the alveolar
10 regeneration or formation and for induction of differentiation of bone marrow cells into alveolar cells, as well as administration of HGF as mentioned above. Hereinafter, HGF gene therapy will be described in detail.

As used herein, "HGF gene" means a gene capable of expressing HGF. To be more specific, there is exemplified a gene wherein cDNA of HGF is integrated
15 in a suitable expression vector (nonvirus vector, virus vector) as described in non-patent literature 2; Japanese patent No. 2,777,678; Biochem. Biophys. Res. Commun., 1989, vol. 163, p. 967; or Biochem. Biophys. Res. Commun., 1990, vol. 172, p. 321. Here, the base sequence of cDNA encoding HGF is described in the above literatures, and also registered in databases such as Genbank. As
20 described in the prior art reference Miyazawa et al. Biochem. Biophys. Res. Commun., 1989, vol. 163, p. 967, the base sequence of cDNA is as follows (SEQ ID No: 1):

```

          gggctcagag ccgactggct ctttaggca ctgactccga acaggattct ttcacccagg
catctcctcc agagggatcc gccagcccgt ccagcagcac c atg tgg gtg acc aaa ctc ctg cca gcc
25 ctg ctg ctg cag cat gtc ctc ctg cat ctc ctc ctg ctc ccc atc gcc atc ccc tat gca gag gga
caa agg aaa aga aga aat aca att cat gaa ttc aaa aaa tca gca aag act acc cta atc aaa
ata gat cca gca ctg aag ata aaa acc aaa aaa gtg aat act gca gac caa tgt gct aat aga
tgt act agg aat aaa gga ctt cca ttc act tgc aag gct ttt gtt ttt gat aaa gca aga aaa caa

```

30079-67

18a

tgc ctc tgg ttc ccc ttc aat agc atg tca agt gga gtg aaa aaa gaa ttt ggc cat gaa ttt gac
 ctc tat gaa aac aaa gac tac att aga aac tgc atc att ggt aaa gga cgc agc tac aag gga
 aca gta tct atc act aag agt ggc atc aaa tgt cag ccc tgg agt tcc atg ata cca cac gaa cac
 agc ttt ttg cct tgc agc tat cgg ggt aaa gac cta cag gaa aac tac tgt cga aat cct cga ggg
 5 gaa gaa ggg gga ccc tgg tgt ttc aca agc aat cca gag gta cgc tac gaa gtc tgt gac att cct
 cag tgt tca gaa gtt gaa tgc atg acc tgc aat ggg gag agt tat cga ggt ctc atg gat cat aca
 gaa tca ggc aag att tgt cag cgc tgg gat cat cag aca cca cac cgg cac aaa ttc ttg cct
 gaa aga tat ccc gac aag ggc ttt gat gat aat tat tgc cgc aat ccc gat ggc cag ccg agg
 cca tgg tgc tat act ctt gac cct cac acc cgc tgg gag tac tgt gca att aaa aca tgc gct gac
 10 aat act atg aat gac act gat gtt cct ttg gaa aca act gaa tgc atc caa ggt caa gga gaa ggc
 tac agg ggc act gtc aat acc att tgg aat gga att cca tgt cag cgt tgg gat tct cag tat cct
 cac gag cat gac atg act cct gaa aat ttc aag tgc aag gac cta cga gaa aat tac tgc cga
 aat cca gat ggg tct gaa tca ccc tgg tgt ttt acc act gat cca aac atc cga gtt ggc tac tgc
 tcc caa att cca aac tgt gat atg tca cat gga caa gat tgt tat cgt ggg aat ggc aaa aat tat
 15 atg ggc aac tta tcc caa aca aga tct gga cta aca tgt tca atg tgg gac aag aac atg gaa
 gac tta cat cgt cat atc ttc tgg gaa cca gat gca agt aag ctg aat gag aat tac tgc cga aat
 cca gat gat gat gct cat gga ccc tgg tgc tac acg gga aat cca ctc att cct tgg gat tat tgc
 cct att tct cgt tgt gaa ggt gat acc aca cct aca ata gtc aat tta gac cat ccc gta ata tct tgt
 gcc aaa acg aaa caa ttg cga gtt gta aat ggg att cca aca cga aca aac ata gga tgg atg
 20 gtt agt ttg aga tac aga aat aaa cat atc tgc gga gga tca ttg ata aag gag agt tgg gtt ctt
 act gca cga cag tgt ttc cct tct cga gac ttg aaa gat tat gaa gct tgg ctt gga att cat gat gtc
 cac gga aga gga gat gag aaa tgc aaa cag gtt ctc aat gtt tcc cag ctg gta tat ggc cct
 gaa gga tca gat ctg gtt tta atg aag ctt gcc agg cct gct gtc ctg gat gat ttt gtt agt acg att
 gat tta cct aat tat gga tgc aca att cct gaa aag acc agt tgc agt gtt tat ggc tgg ggc tac
 25 act gga ttg atc aac tat gat ggc cta tta cga gtg gca cat ctc tat ata atg gga aat gag aaa
 tgc agc cag cat cat cga ggg aag gtg act ctg aat gag tct gaa ata tgt gct ggg gct gaa
 aag att gga tca gga cca tgt gag ggg gat tat ggt ggc cca ctt gtt tgt gag caa cat aaa atg
 aga atg gtt ctt ggt gtc att gtt cct ggt cgt gga tgt gcc att cca aat cgt cct ggt att ttt gtc cga
 gta gca tat tat gca aaa tgg ata cac aaa att att tta aca tat aag gta cca cag tca tag
 30 ctgaagtaag tgtgtctgaa gcacccacca atacaactgt cttttacatg aagatttcag agaattgtgga
 atttaaaatg tcacttacaa caatcctaag acaactactg gagagtcatg tttgttgaaa ttctcattaa

30079-67

18b

tgtttatggg tgtttctgt tgtttggtt gtcagtgtta tttgtcaat gttgaagtga attaagggtac atgcaagtgt
aataacatat ctccgaaga tacttgaatg gattaaaaaa acacacaggt atatttgctg gatgataa.

Based on the above sequence data, it is therefore possible to carry out,
for example, RT-PCR to mRNA from liver, etc., by use of a proper DNA segment as a
5 PCR primer, whereby cDNA cloning of HGF is performed. Such cloning could be
easily done by those skilled in the art according to fundamental textbooks such as

Molecular Cloning 2nd Edit., published by Cold Spring Harbor Laboratory Press (1989).

Further, the HGF gene used in the present invention is not limited to the above-mentioned genes, and any HGF gene can
5 be used as the HGF gene of the present invention so long as it expresses a protein having the substantially the same activity with that of HGF. That is, among DNAs which can hybridize with the above-mentioned cDNA under stringent conditions and DNAs encoding a protein wherein one to plural amino acids (preferably
10 several amino acids) in the amino acid sequence encoded by the above-mentioned cDNA are substituted, deleted, added and/or inserted, any DNA encoding a protein having an activity of HGF is included in the scope of the HGF gene used in the present invention. Such DNAs can be easily obtained by common
15 hybridization method, PCR method and the like, specifically by reference to fundamental textbooks such as Molecular Cloning mentioned above.

HGF genes used in the present invention can be applied to regeneration or formation of alveolar cells and induction
20 of differentiation of bone marrow cells into alveolar cells, in the same manner as in the above-mentioned HGF protein.

When a gene therapy agent comprising HGF gene as an active ingredient is administered to a patient, such administration can be conducted in the conventional manner described in, for
25 example, Basic Technology of Gene Therapy, Separate Volume of Experimental Medicine published by Yodosha, Japan, 1996; Gene Introduction and Expression Analysis Method, Separate Volume of Experimental Medicine, published by Yodosha, Japan, 1997; Gene Therapy Development Research Handbook, edited by The Japan

Society of Gene Therapy, published by NTS, Japan, 1999.

The dosage form may include a variety of known forms suitable for each administration form mentioned above. DNA content in the preparation can be appropriately controlled, depending on the target disease, age and body weight of patients, etc., and usually the DNA content in accordance with the present invention is 0.0001 to 100 mg, preferably 0.001 to 10 mg.

Further, HGF gene and HGF may be used each independently or in combination.

The present invention will be illustrated by the following Examples, but it is not limited thereto. The percentage (%) means % by mass unless otherwise indicated.

Example

Reconstitution of bone marrow:

Mice transgenic for enhanced green fluorescent protein (GFP) on a C57BL/6 strain background were established at Osaka University, Japan. Liver cells of fetal livers harvested from day 13.5 GFP embryos were transplanted to C57BL/6 male mice which were irradiated using doses of 12 Gy before the transplantation, according to the method by Morishita, et. al as described in Hypertension, 1999, vol. 33, p.1379-1384. Those mice in which over 95 % of the circulating white blood cells (peripheral leukocytes) were completely replaced with bone marrow cells of GFP mouse origin three weeks after the transplantation were served as recipient mice in the experiment.

Induction of pulmonary emphysema and treatment

Experimental pulmonary emphysema was induced by intranasal instillation of porcine pancreas elastase into recipient mice. Three weeks after the elastase instillation, the recipient mice exhibited emphysematous changes in the lungs. At this point, the recipient mice with induced pulmonary emphysema were randomly divided into two groups, i.e. vehicle administration group and HGF administration group, which were injected intraperitoneally with a balanced diet and with HGF respectively, at a dose of 1 mg/kg once daily for 12 days.

Histological anatomy

Lungs of the recipient mice were fixed with 4% paraformaldehyde-PBS (phosphate buffered saline) at a pressure of 20 cm H₂O, and paraffin sections were prepared according to the conventional method. The paraffin sections were stained with hematoxylin-eosin (HE). GFP was detected using anti-GFP antibody (Abcam, Cambridge, UK) and visualized with 3,3'-diaminobenzidine. The number of GFP-positive cells in 200 alveoli separated from each mouse was counted (each group n=5). The extent of the emphysematous lesions was assessed by measuring the mean linear intercept (hereinafter abbreviated as Lm) of alveolar septation according to the method of Thurlbeck (see Ono, M. et. al, Circulation 2002, vol. 106, p. 1264-1269). That is, Lm of the alveolar cell in 20 visual fields randomly sampled on two slides from each mouse was measured at 400x magnification. The total distance divided by the number of alveolar intercepts gave Lm. Histological evaluations were performed blindly by three observers (K.I., T.S. and H.K.).

Immunofluorescence of the frozen sections staining was

performed to identify the phenotype of the GFP-positive cells. Anti-cytokeratin 5 and 8 antibody was purchased from Chemicon (Temecula, CA, USA), and anti-CD34 and anti-CD45 antibodies from Pharmingen (San Diego, CA, USA).

5

Statistical analysis

The data were expressed as the mean $\pm$ standard error. Comparisons were made by analysis of variance, and when overall differences were identified, multiple contrasts with a Bonferroni adjustment were used to identify which groups were significantly different. Statistical significance was defined as $p < 0.05$.

Results

15 In the observations of tissue sections using an optical microscope, alveoli in recipient mice with elastase-induced pulmonary emphysema were destroyed, and each alveolus was enlarged about 3- to 5-fold compared to that which had not been treated with elastase. On the other hand, the alveolus in HGF
20 administration group is almost the same with that in no elastase treatment group (see Fig. 1). The mean linear intercept in the pulmonary emphysema-induced recipient mice was shown in Fig. 2. The mean linear intercept in the recipient mice with elastase-induced pulmonary emphysema was enlarged about
25 1.7-fold, and that in the HGF administration group was almost the same, compared with that in no elastase treatment group.

The rate of GFP-positive alveoli relative to total alveoli in the lungs of recipient mice was shown in Fig.3. The rate of GFP positive cells was approximately 1% in the recipient

30079-67

23

mice receiving no elastase treatment. The rate of GFP positive cells was increased approximately by 10% in the recipient mice with elastase-induced pulmonary emphysema, while that in the HGF administration group was increased approximately by 17.5%.

5 Further, histological observation results by immunofluorescence staining revealed that such GFP positive cells were differentiated into alveolar epithelial cells and pulmonary capillary endothelial cells from GFP mice-derived bone marrow cells. These results show that HGF promotes
10 induction of differentiation of bone marrow cells into alveoli (alveolar epithelial cells and pulmonary capillary endothelial cells, etc.).

Industrial applicability

15 The differentiation-inducing agent of the present invention induces differentiation of bone marrow cells into alveolar cells and is useful as an agent for the regeneration of alveoli destroyed due to pulmonary emphysema, etc. Also, alveolar cells differentiation-induced from bone marrow cells
20 can be utilized as cells for transplantation in the field of regenerative medicine.

SEQUENCE LISTING IN ELECTRONIC FORM

In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 30079-67 Seq 19-MAR-12 v1.txt).

A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

30079-67

24

CLAIMS:

1. A composition for inducing differentiation of bone marrow cells into alveolar cells, comprising hepatocyte growth factor and a pharmaceutically acceptable additive, the hepatocyte growth factor being
 - 5 (a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or
 - (b) hepatocyte growth factor comprising an amino acid sequence of 90% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1 and having an activity to
10 induce differentiation of bone marrow cells into alveolar cells.
2. A composition for inducing differentiation of bone marrow cells into alveolar cells, comprising hepatocyte growth factor and a pharmaceutically acceptable additive, the hepatocyte growth factor being
 - 15 (a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or
 - (b) hepatocyte growth factor comprising an amino acid sequence of 95% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1 and having an activity to induce differentiation of bone marrow cells into alveolar cells.
- 20 3. The differentiation-inducing composition according to claim 1 or 2, wherein the alveolar cells are alveolar epithelial cells.
4. The differentiation-inducing composition according to any one of claims 1 to 3, which is a composition for promoting alveolar regeneration/formation.
5. A hepatocyte growth factor for use in inducing differentiation of bone
25 marrow cells into alveolar cells, which is

30079-67

25

(a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or

(b) hepatocyte growth factor comprising an amino acid sequence of 90% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1 and having an activity to induce differentiation of bone marrow cells into alveolar cells.

6. A hepatocyte growth factor for use in inducing differentiation of bone marrow cells into alveolar cells, which is

(a) hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1, or

(b) hepatocyte growth factor comprising an amino acid sequence of 95% or more identity with the amino acid sequence of the hepatocyte growth factor encoded by the nucleotide sequence of SEQ ID NO: 1 and having an activity to induce differentiation of bone marrow cells into alveolar cells.

7. The hepatocyte growth factor according to claim 5 or 6, wherein the alveolar cells are alveolar epithelial cells.

8. The hepatocyte growth factor according to any one of claims 5 to 7, which is a hepatocyte growth factor for use in promoting alveolar regeneration/formation.



Fig. 1**5 Fig. 2**

Fig. 3